



Corporate Profile

illumina (NASDAQ: ILMN) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.

Contact Information

For Company Information

Jacque Ross
Vice President, Investor Relations
illumina, Inc.
Phone: 858.255.5243
E-mail: rchambers@illumina.com

For Stock Based Inquiries

Computershare Trust Company, N.A.
250 Royall Street
Canton, MA 02021
Phone: 800.251.4215
Corporate Website: <http://www.computershare.com>

Stock Performance

ILMN (Common Stock)

Exchange	NASDAQ GS (US Dollar)
Price	\$331.59
Change (%)	▼ 5.33 (1.58%)
Volume	241,417
52 Week Low	\$207.51
Market Cap	\$48,743,730,000
Rolling EPS	4.62
PE Ratio	71.7727
Shares Outstanding	147,000,000
Data as of 12/13/18 12:28 p.m. ET	



Recent Headlines

Date	Title
12/06/18	illumina Announces a New Genotyping Array and Scientific Contribution to Three Genome Centers to Support the All of Us Research Program
11/13/18	illumina to Webcast Upcoming Investor Conference Presentations
11/01/18	illumina to Acquire Pacific Biosciences for Approximately \$1.2 Billion, Broadening Access to Long-Read Sequencing and Accelerating Scientific Discovery
10/30/18	illumina Launches TruSight Oncology 500 to Power Comprehensive, Accurate, Pan-Cancer Tumor Profiling

Events


There are currently no events scheduled.

Analyst Coverage

Firm	Analyst
BANK OF AMERICA	DERIK de BRUIN
BARCLAYS	JACK MEEHAN
BTIG	DANE LEONE
CANTOR FITZGERALD	SUNG JI NAM
CITI	DAN ARIAS
COWEN AND COMPANY	DOUG SCHENKEL
CREDIT SUISSE	VAMIL DIVAN
FIRST ANALYSIS SECURITIES CORP	TRACY MARSHBANKS
GOLDMAN SACHS & CO.	ISAAC RO
ISI GROUP	ROSS MUKEN
J.P.MORGAN	TYCHO W. PETERSON
JANNEY CAPITAL MARKETS	PAUL KNIGHT
JMP SECURITIES	J.T. HARESCO
LEERINK SWANN LLC	DAN LEONARD
MAXIM GROUP	BRYAN BROKMEIER
MIZUHO SECURITIES	PETER LAWSON
MORGAN STANLEY	STEVE BEUCHAW
MORNINGSTAR INC.	CHARLIE MILLER
PIPER JAFFRAY	WILLIAM R. QUIRK
ROBERT W. BAIRD & CO., INC.	JEFFREY ELLIOT
STIFEL	MIROSLAVA MINKOVA
WEDBUSH SECURITIES	ZARAK KHURSHID
WELLS FARGO	TIM EVANS
WILLIAM BLAIR & COMPANY, LLC	AMANDA MURPHY

Analyst Estimates / Ratings

Mean Recommendation: 2.0



Unable to fulfill request.

Management

Jay T. Flatley

Chief Executive Officer

Board of Directors

William H. Rastetter, Ph.D.

Chairman

Jay T. Flatley

Francis A. deSouza

Blaine Bowman

Daniel M. Bradbury

Director Since January 2004

Karin Eastham

Robert S. Epstein, M.D.

Jeff Huber

Gerald Möller, Ph.D.

David R. Walt, Ph.D.

Roy Whitfield

